Ubiquitin Ligases in Cancer: Ushers for Degradation

REFERENCES

• Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998; 67: 425–479
   PubMed Web of Science ®Google Scholar
• Hershko A., Heller H., Elias S., Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 1983; 258: 8206–8214
   Google Scholar
• Hoppe T. Multiubiquitylation by E4 enzymes: ‘one size’ doesn't fit all. Trends Biochem. Sci. 2005; 30: 183–187
   PubMed Web of Science ®Google Scholar
• Koegl M., Hoppe T., Schlenker S., Ulrich H. D., Mayer T. U., Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999; 96: 635–644
   PubMed Web of Science ®Google Scholar
• Hicke L., Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 2003; 19: 141–172
   PubMed Web of Science ®Google Scholar
• Pickart C. M., Fushman D. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. 2004; 8: 610–616
   PubMed Web of Science ®Google Scholar
• Hicke L., Schubert H. L., Hill C. P. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol. 2005; 6: 610–621
   PubMed Web of Science ®Google Scholar
• Kirkpatrick D. S., Hathaway N. A., Hanna J., Elsasser S., Rush J., et al. Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat. Cell Biol. 2006; 8: 700–710
   PubMed Web of Science ®Google Scholar
• Hofmann R. M., Pickart C. M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 1990; 96: 645–653
   Google Scholar
• Deng L., Wang C., Spencer E., Yang L., Braun A., You J., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351–361
   PubMed Web of Science ®Google Scholar
• Ardley H. C., Robinson P. A. E3 ubiquitin ligases. Essays Biochem. 2005; 41: 15–30
   PubMed Web of Science ®Google Scholar
• Xia Z. P., Chen Z. J. TRAF2: a double-edged sword?. Sci STKE 2005; e7
   Google Scholar
• Fang S., Jensen J. P., Ludwig R. L., Vousden K. H., Weissman A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 2000; 275: 8945–8951
   PubMed Web of Science ®Google Scholar
• Skowyra D., Craig K. L., Tyers M., Elledge S. J., Harper J. W. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 1997; 91: 209–219
   PubMed Web of Science ®Google Scholar
• Deshaies R. J. SCF and Cullin/Ring H2–based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 1999; 15: 435–467
   PubMed Web of Science ®Google Scholar
• Jiang J., Ballinger C. A., Wu Y., Dai Q., Cyr D. M., Hohfeld J., Patterson C. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 2001; 276: 42938–42944
   PubMed Web of Science ®Google Scholar
• Murata S., Minami Y., Minami M., Chiba T., Tanaka K. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2001; 2: 1133–1138
   PubMed Web of Science ®Google Scholar
• Lu Z., Xu S., Joazeiro C., Cobb M. H., Hunter T., The P HD. domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 2002; 9: 945–956
   PubMed Web of Science ®Google Scholar
• Wertz I. E., O'Rourke K. M., Zhou H., Eby M., Aravind L., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694–699
   PubMed Web of Science ®Google Scholar
• Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004; 427: 167–171
   PubMed Web of Science ®Google Scholar
• Kaelin W. G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 2005; 74: 115–128
   PubMed Web of Science ®Google Scholar
• Ohh M., Park C. W., Ivan M., Hoffman M. A., Kim T. Y., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2000; 2: 423–427
   PubMed Web of Science ®Google Scholar
• Kibel A., Iliopoulos O., DeCaprio J. A., Kaelin W. G., Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin BC. Science 1995; 269: 1444–1446
   PubMed Web of Science ®Google Scholar
• Duan D. R., Pause A., Burgess W. H., Aso T., Chen D. Y., et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995; 269: 1402–1406
   PubMed Web of Science ®Google Scholar
• Pause A., Lee S., Worrell R. A., Chen D. Y., Burgess W. H., Linehan W. M., Klausner R. D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl. Acad. Sci. USA 1997; 94: 2156–2161
   PubMed Web of Science ®Google Scholar
• Kamura T., Koepp D. M., Conrad M. N., Skowyra D., Moreland R. J., et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999; 284: 657–661
   PubMed Web of Science ®Google Scholar
• Maxwell P. H., Wiesener M. S., Chang G. W., Clifford S. C., Vaux E. C., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–275
   PubMed Web of Science ®Google Scholar
• Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464–468
   PubMed Web of Science ®Google Scholar
• Jaakkola P., Mole D. R., Tian Y. M., Wilson M. I., Gielbert J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468–472
   PubMed Web of Science ®Google Scholar
• Yu F., White S. B., Zhao Q., Lee F. S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 2001; 98: 9630–9635
   PubMed Web of Science ®Google Scholar
• Masson N., Willam C., Maxwell P. H., Pugh C. W., Ratcliffe P. J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001; 20: 5197–5206
   PubMed Web of Science ®Google Scholar
• Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W. G., Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1: 237–246
   PubMed Web of Science ®Google Scholar
• Maranchie J. K., Vasselli J. R., Riss J., Bonifacino J. S., Linehan W. M., Klausner R. D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1: 247–255
   PubMed Web of Science ®Google Scholar
• Kondo K., Kim W. Y., Lechpammer M., Kaelin W. G., Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003; 1: E83
   PubMed Web of Science ®Google Scholar
• Zimmer M., Doucette D., Siddiqui N., Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Mol. Cancer Res. 2004; 2: 89–95
   PubMed Web of Science ®Google Scholar
• Kim W., Kaelin W. G., Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 2003; 13: 55–60
   PubMed Web of Science ®Google Scholar
• Hergovich A., Lisztwan J., Barry R., Ballschmieter P., Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 2003; 5: 64–70
   PubMed Web of Science ®Google Scholar
• Na X., Duan H. O., Messing E. M., Schoen S. R., Ryan C. K., et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J. 2003; 22: 4249–4259
   PubMed Web of Science ®Google Scholar
• Calzada M. J., Esteban M. A., Feijoo-Cuaresma M., Castellanos M. C., et al. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 2006; 66: 1553–1560
   PubMed Web of Science ®Google Scholar
• Nakamura E., Abreu-e-Lima P., Awakura Y., Inoue T., Kamoto T., et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am. J. Pathol. 2006; 168: 574–584
   PubMed Web of Science ®Google Scholar
• Thien C. B., Langdon W. Y. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem. J. 2005; 391: 153–166
   PubMed Web of Science ®Google Scholar
• Joazeiro C. A., Wing S. S., Huang H., Leverson J. D., Hunter T., Liu Y. C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999; 286: 309–312
   PubMed Web of Science ®Google Scholar
• Levkowitz G., Waterman H., Ettenberg S. A., Katz M., Tsygankov A. Y., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 1999; 4: 1029–1040
   PubMed Web of Science ®Google Scholar
• Rao N., Ghosh A. K., Ota S., Zhou P., Reddi A. L., et al. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J. 2001; 20: 7085–7095
   PubMed Web of Science ®Google Scholar
• Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P. P., Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol. 2003; 5: 461–466
   PubMed Web of Science ®Google Scholar
• Peschard P., Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003; 3: 519–523
   PubMed Web of Science ®Google Scholar
• Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006; 66: 283–289
   PubMed Web of Science ®Google Scholar
• Thien C. B., Walker F., Langdon W. Y. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol. Cell 2001; 7: 355–365
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Lane D., Levine A. J. Surfing the p53 network. Nature 2000; 408: 307–310
   PubMed Web of Science ®Google Scholar
• Brooks C. L., Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 2006; 21: 307–315
   PubMed Web of Science ®Google Scholar
• Leng R. P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J. M., Lozano G., Hakem R., Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112: 779–791
   PubMed Web of Science ®Google Scholar
• Dornan D., Bheddah S., Newton K., Ince W., Frantz G. D., Dowd P., Koeppen H., Dixit V. M., French D. M. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004; 64: 7226–7230
   PubMed Web of Science ®Google Scholar
• Chen D., Kon N., Li M., Zhang W., Qin J., Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121: 1071–1083
   PubMed Web of Science ®Google Scholar
• Jones S. N., Roe A. E., Donehower L. A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206–208
   PubMed Web of Science ®Google Scholar
• Montes d e, Oca Luna R., Wagner D. S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203–206
   PubMed Web of Science ®Google Scholar
• Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26: 3453–3459
   PubMed Web of Science ®Google Scholar
• Bond G. L., Hu W., Bond E. E., Robins H., Lutzker S. G., Arva N. C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591–602
   PubMed Web of Science ®Google Scholar
• Menin C., Scaini M. C., De Salvo G. L., Biscuola M., Quaggio M., et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J. Natl. Cancer Inst. 2006; 98: 285–288
   PubMed Web of Science ®Google Scholar
• Bougeard G., Baert-Desurmont S., Tournier I., Vasseur S., Martin C., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet. 2006; 43: 531–533
   PubMed Web of Science ®Google Scholar
• Williams S. A., McConkey D. J. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 2003; 63: 7338–7344
   PubMed Web of Science ®Google Scholar
• Abbas A. R., Baldwin D., Ma Y., Ouyang W., Gurney A., et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 2005; 6: 319–331
   PubMed Web of Science ®Google Scholar
• Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445–1449
   PubMed Web of Science ®Google Scholar
• Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462
   PubMed Web of Science ®Google Scholar
• Salvesen G. S., Duckett C. S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002; 3: 401–410
   PubMed Web of Science ®Google Scholar
• LaCasse E. C., Baird S., Korneluk R. G., MacKenzie A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–3259
   PubMed Web of Science ®Google Scholar
• Tamm I., Kornblau S. M., Segall H., Krajewski S., Welsh K., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 2000; 6: 1796–1803
   PubMed Web of Science ®Google Scholar
• Tamm I., Richter S., Scholz F., Schmelz K., Oltersdorf D., et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J. 2004; 5: 489–495
   PubMedGoogle Scholar
• Vaux D. L., Silke J. IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell Biol. 2005; 6: 287–297
   PubMed Web of Science ®Google Scholar
• MacFarlane M., Merrison W., Bratton S. B., Cohen G. M. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J. Biol. Chem. 2002; 277: 36611–36616
   PubMed Web of Science ®Google Scholar
• Bartke T., Pohl C., Pyrowolakis G., Jentsch S. Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol. Cell 2004; 14: 801–811
   PubMed Web of Science ®Google Scholar
• Hao Y., Sekine K., Kawabata A., Nakamura H., Ishioka T., et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat. Cell Biol. 2004; 6: 849–860
   PubMed Web of Science ®Google Scholar
• Suzuki Y., Nakabayashi Y., Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA 2001; 98: 8662–8667
   PubMed Web of Science ®Google Scholar
• Huang H., Joazeiro C. A., Bonfoco E., Kamada S., Leverson J. D., Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 2000; 275: 26661–26664
   PubMed Web of Science ®Google Scholar
• Vaux D. L., Silke J. IAPs–the ubiquitin connection. Cell Death Differ. 2005; 12: 1205–1207
   PubMed Web of Science ®Google Scholar
• Silke J., Kratina T., Chu D., Ekert P. G., Day C. L., et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc. Natl. Acad. Sci. USA 2005; 102: 16182–16187
   PubMed Web of Science ®Google Scholar
• Yang Q. H., Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J. Biol. Chem. 2004; 279: 16963–16970
   PubMed Web of Science ®Google Scholar
• Wilson R., Goyal L., Ditzel M., Zachariou A., Baker D. A., et al. The DIAP1 RING finger mediates ubiquitination of Dronc and is indispensable for regulating apoptosis. Nat. Cell Biol. 2002; 14: 14
   Google Scholar
• Ditzel M., Wilson R., Tenev T., Zachariou A., Paul A., Deas E., Meier P. Degradation of DIAP1 by the N-end rule pathway is essential for regulating apoptosis. Nat. Cell Biol. 2003; 5: 467–473
   PubMed Web of Science ®Google Scholar
• Lisi S., Mazzon I., White K. Diverse Domains of THREAD/DIAP1 Are Required to Inhibit Apoptosis Induced by REAPER and HID in Drosophila. Genetics 2000; 154: 669–678
   PubMed Web of Science ®Google Scholar
• Goyal L., McCall K., Agapite J., Hartwieg E., Steller H. Induction of apoptosis by Drosophila reaper, hid and grim through inhibition of IAP function. EMBO J. 2000; 19: 589–597
   PubMed Web of Science ®Google Scholar
• Cory S., Huang D. C., Adams J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590–8607
   PubMed Web of Science ®Google Scholar
• Breitschopf K., Zeiher A. M., Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. a functional consequence on apoptosis induction. J. Biol. Chem. 2000; 275: 21648–21652
   Google Scholar
• Dimmeler S., Breitschopf K., Haendeler J., Zeiher A. M. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J. Exp. Med. 1999; 189: 1815–1822
   PubMed Web of Science ®Google Scholar
• Lim M. S., Elenitoba-Johnson K. S. Ubiquitin ligases in malignant lymphoma. Leuk. Lymphoma. 2004; 45: 1329–1339
   PubMed Web of Science ®Google Scholar
• Marshansky V., Wang X., Bertrand R., Luo H., Duguid W., et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J. Immunol. 2001; 166: 3130–3142
   PubMed Web of Science ®Google Scholar
• Zhong Q., Gao W., Du F., Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085–1095
   PubMed Web of Science ®Google Scholar
• Shmueli A., Oren M. Life, death, and ubiquitin: taming the mule. Cell 2005; 121: 963–965
   PubMed Web of Science ®Google Scholar
• Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181–190
   PubMed Web of Science ®Google Scholar
• Tschopp J., Irmler M., Thome M. Inhibition of fas death signals by FLIPs. Curr. Opin. Immunol. 1998; 10: 552–558
   PubMed Web of Science ®Google Scholar
• Chang L., Kamata H., Solinas G., Luo J. L., Maeda S., et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601–613
   PubMed Web of Science ®Google Scholar
• Li Q., Verma I. M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002; 2: 725–734
   PubMed Web of Science ®Google Scholar
• Karin M., Cao Y., Greten F. R., Li Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Rev. 2002; 2: 301–310
   Web of Science ®Google Scholar
• Gao M., Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol. Cell 2005; 19: 581–593
   PubMed Web of Science ®Google Scholar
• Liu Y. C., Penninger J., Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat. Rev. Immunol. 2005; 5: 941–952
   PubMed Web of Science ®Google Scholar
• Arch R. H., Gedrich R. W., Thompson C. B. Tumor necrosis factor receptor-associated factors (TRAFs)–a family of adapter proteins that regulates life and death. Genes Dev. 1998; 12: 2821–2830
   PubMed Web of Science ®Google Scholar
• Kelliher M. A., Grimm S., Ishida Y., Kuo F., Stanger B. Z., Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297–303
   PubMed Web of Science ®Google Scholar
• Tada K., Okazaki T., Sakon S., Kobarai T., Kurosawa K., et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa Bactivation and protection from cell death. J. Biol. Chem. 2001; 276: 36530–36534
   PubMed Web of Science ®Google Scholar
• Ea C. K., Deng L., Xia Z. P., Pineda G., Chen Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 2006; 22: 245–257
   PubMed Web of Science ®Google Scholar
• Wu C. J., Conze D. B., Li T., Srinivasula S. M., Ashwell J. D. NEMO is a sensor of Lys 63-linked polyubiquitination and functions in NF-kappaB activation. Nat. Cell Biol. 2006; 8: 398–406
   PubMed Web of Science ®Google Scholar
• Kanayama A., Seth R. B., Sun L., Ea C. K., Hong M., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 2004; 15: 535–548
   PubMed Web of Science ®Google Scholar
• Li H., Kobayashi M., Blonska M., You Y., Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J. Biol. Chem. 2006; 281: 13636–13643
   PubMedGoogle Scholar
• Li X., Yang Y., Ashwell J. D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002; 416: 345–347
   PubMed Web of Science ®Google Scholar
• Krappmann D., Scheidereit C. A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep. 2005; 6: 321–326
   PubMed Web of Science ®Google Scholar
• Uren A. G., O'Rourke K., Aravind L. A., Pisabarro M. T., Seshagiri S., Koonin E. V., Dixit V. M. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell 2000; 6: 961–967
   PubMed Web of Science ®Google Scholar
• Ruefli-Brasse A. A., French D. M., Dixit V. M. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003; 302: 1581–1584
   PubMed Web of Science ®Google Scholar
• Ruland J., Duncan G. S., Wakeham A., Mak T. W. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003; 19: 749–758
   PubMed Web of Science ®Google Scholar
• Newton K., Dixit V. M. Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes. Curr. Biol. 2003; 13: 1247–1251
   PubMed Web of Science ®Google Scholar
• Egawa T., Albrecht B., Favier B., Sunshine M. J., Mirchandani K., et al. Requirement for CARMA1 in antigen receptor-induced NF-kappa Bactivation and lymphocyte proliferation. Curr. Biol. 2003; 13: 1252–1258
   PubMed Web of Science ®Google Scholar
• Jun J. E., Wilson L. E., Vinuesa C. G., Lesage S., Blery M., et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity 2003; 18: 751–762
   PubMedGoogle Scholar
• Hara H., Wada T., Bakal C., Kozieradzki I., Suzuki S., Suzuki N., et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003; 18: 763–775
   PubMed Web of Science ®Google Scholar
• Isaacson P. G. Update on MALT lymphomas. Best Pract. Res. Clin. Haematol. 2005; 18: 57–68
   PubMed Web of Science ®Google Scholar
• Akagi T., Motegi M., Tamura A., Suzuki R., Hosokawa Y., et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785–5794
   PubMed Web of Science ®Google Scholar
• Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J. M., et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601–3609
   PubMed Web of Science ®Google Scholar
• Morgan J. A., Yin Y., Borowsky A. D., Kuo F., Nourmand N., et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 1999; 59: 6205–6213
   PubMed Web of Science ®Google Scholar
• Zhou H., Du M. Q., Dixit V. M. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005; 7: 425–431
   PubMed Web of Science ®Google Scholar
• Nakayama K. I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nature Rev. 2006; 6: 369–381
   Web of Science ®Google Scholar
• Kaiser P., Wohlschlegel J. Identification of ubiquitination sites and determination of ubiquitin-chain architectures by mass spectrometry. Methods Enzymol. 2005; 399: 266–277
   PubMed Web of Science ®Google Scholar
• Welcker M., Singer J., Loeb K. R., Grim J., Bloecher A., et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 2003; 12: 381–392
   PubMed Web of Science ®Google Scholar
• Welcker M., Orian A., Jin J., Grim J. E., Harper J. W., et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 2004; 101: 9085–9090
   PubMed Web of Science ®Google Scholar
• Yada M., Hatakeyama S., Kamura T., Nishiyama M., Tsunematsu R., et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23: 2116–2125
   PubMed Web of Science ®Google Scholar
• Wei W., Jin J., Schlisio S., Harper J. W., Kaelin W. G., Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005; 8: 25–33
   PubMed Web of Science ®Google Scholar
• Bahram F., von der Lehr N., Cetinkaya C., Larsson L. G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95: 2104–2110
   PubMed Web of Science ®Google Scholar
• Rajagopalan H., Jallepalli P. V., Rago C., Velculescu V. E., Kinzler K. W., Vogelstein B., Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428: 77–81
   PubMed Web of Science ®Google Scholar
• Spruck C. H., Strohmaier H., Sangfelt O., Muller H. M., Hubalek M., et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002; 62: 4535–4539
   PubMed Web of Science ®Google Scholar
• Kemp Z., Rowan A., Chambers W., Wortham N., Halford S., et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 2005; 65: 11361–11366
   PubMed Web of Science ®Google Scholar
• Bloom J., Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 2003; 13: 41–47
   PubMed Web of Science ®Google Scholar
• Hao B., Zheng N., Schulman B. A., Wu G., Miller J. J., Pagano M., Pavletich N. P. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell 2005; 20: 9–19
   PubMed Web of Science ®Google Scholar
• Kitajima S., Kudo Y., Ogawa I., Bashir T., Kitagawa M., et al. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation. Am. J. Pathol. 2004; 165: 2147–2155
   PubMed Web of Science ®Google Scholar
• Shapira M., Ben-Izhak O., Linn S., Futerman B., Minkov I., Hershko D. D. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005; 103: 1336–1346
   PubMed Web of Science ®Google Scholar
• Slotky M., Shapira M., Ben-Izhak O., Linn S., Futerman B., Tsalic M., Hershko D. D. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res. 2005; 7: R737–744
   PubMed Web of Science ®Google Scholar
• Thornton B. R., Ng T. M., Matyskiela M. E., Carroll C. W., Morgan D. O., Toczyski D. P. An architectural map of the anaphase-promoting complex. Genes Dev. 2006; 20: 449–460
   PubMed Web of Science ®Google Scholar
• Ohta T., Michel J. J., Schottelius A. J., Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell 1999; 3: 535–541
   PubMed Web of Science ®Google Scholar
• Leverson J. D., Joazeiro C. A., Page A. M., Huang H., Hieter P., Hunter T. The APC11 RING-H2 finger mediates E2-dependent ubiquitination. Mol. Biol. Cell 2000; 11: 2315–2325
   PubMed Web of Science ®Google Scholar
• Gmachl M., Gieffers C., Podtelejnikov A. V., Mann M., Peters J. M. The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are sufficient to ubiquitinate substrates of the anaphase-promoting complex. Proc. Natl. Acad. Sci. USA 2000; 97: 8973–8978
   PubMed Web of Science ®Google Scholar
• Visintin R., Prinz S., Amon A. CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science 1999; 278: 460–463
   Web of Science ®Google Scholar
• Reimann J. D., Freed E., Hsu J. Y., Kramer E. R., Peters J. M., Jackson P. K. Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell 2001; 105: 645–655
   PubMed Web of Science ®Google Scholar
• Golan A., Yudkovsky Y., Hershko A. The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J. Biol. Chem. 2002; 277: 15552–15557
   PubMed Web of Science ®Google Scholar
• Kraft C., Herzog F., Gieffers C., Mechtler K., Hagting A., Pines J., Peters J. M. Mitotic regulation of the human anaphase-promoting complex by phosphorylation. EMBO J. 2003; 22: 6598–6609
   PubMed Web of Science ®Google Scholar
• Vodermaier H. C. APC/C and SCF: controlling each other and the cell cycle. Curr. Biol. 2004; 14: R787–796
   PubMed Web of Science ®Google Scholar
• Eldridge A. G., Loktev A. V., Hansen D. V., Verschuren E. W., Reimann J. D., Jackson P. K. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1. Cell 2006; 124: 367–380
   PubMed Web of Science ®Google Scholar
• Parvin J. D. Overview of history and progress in BRCA1 research: the first BRCA1 decade. Cancer Biol. Ther. 2004; 3: 505–508
   PubMed Web of Science ®Google Scholar
• Billack B., Monteiro A. N. BRCA1 in breast and ovarian cancer predisposition. Cancer Lett. 2005; 227: 1–7
   PubMed Web of Science ®Google Scholar
• Wu L. C., Wang Z. W., Tsan J. T., Spillman M. A., Phung A., et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 1996; 14: 430–440
   PubMed Web of Science ®Google Scholar
• Xia Y., Pao G. M., Chen H. W., Verma I. M., Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Biol. Chem. 2003; 278: 5255–5263
   PubMed Web of Science ®Google Scholar
• Starita L. M., Parvin J. D. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr. Opin. Cell Biol. 2003; 15: 345–350
   PubMed Web of Science ®Google Scholar
• Nishikawa H., Ooka S., Sato K., Arima K., Okamoto J., et al. Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J. Biol. Chem. 2004; 279: 3916–3924
   PubMed Web of Science ®Google Scholar
• Wu-Baer F., Lagrazon K., Yuan W., Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 2003; 278: 34743–34746
   PubMed Web of Science ®Google Scholar
• Brzovic P. S., Meza J., King M. C., Klevit R. E. The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. J. Biol. Chem. 1998; 273: 7795–7799
   PubMed Web of Science ®Google Scholar
• Brzovic P. S., Meza J. E., King M. C., Klevit R. E. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J. Biol. Chem. 2001; 276: 41399–41406
   Google Scholar
• Goldenberg S. J., Cascio T. C., Shumway S. D., Garbutt K. C., Liu J., Xiong Y., Zheng N. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 2004; 119: 517–528
   PubMedGoogle Scholar
• Read M. A., Brownell J. E., Gladysheva T. B., Hottelet M., Parent L. A., et al. Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol. Cell Biol. 2000; 20: 2326–2333
   PubMed Web of Science ®Google Scholar
• Wu K., Chen A., Pan Z. Q. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J. Biol. Chem. 2000; 275: 32317–32324
   PubMed Web of Science ®Google Scholar
• Lyapina S., Cope G., Shevchenko A., Serino G., Tsuge T., et al. Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. Science 2001; 292: 1382–1385
   PubMed Web of Science ®Google Scholar
• Liu J., Furukawa M., Matsumoto T., Xiong Y. NEDD8 modification of CUL1 dissociates p120(CAND1), an inhibitor of CUL1-SKP1 binding and SCF ligases. Mol. Cell 2002; 10: 1511–1518
   PubMed Web of Science ®Google Scholar
• Zheng J., Yang X., Harrell J. M., Ryzhikov S., Shim E. H., et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol. Cell 2002; 10: 1519–1526
   PubMed Web of Science ®Google Scholar
• Cope G. A., Deshaies R. J. Targeted silencing of Jab1/Csn5 in human cells downregulates SCF activity through reduction of F-box protein levels. BMC Biochem. 2006; 7: 1
   PubMedGoogle Scholar
• Richardson K. S., Zundel W. The emerging role of the COP9 signalosome in cancer. Mol. Cancer Res. 2005; 3: 645–653
   PubMed Web of Science ®Google Scholar
• Bignell G. R., Warren W., Seal S., Takahashi M., Rapley E., et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 2000; 25: 160–165
   PubMed Web of Science ®Google Scholar
• Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665–677
   PubMed Web of Science ®Google Scholar
• Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793–796
   PubMed Web of Science ®Google Scholar
• Brummelkamp T. R., Nijman S. M., Dirac A. M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797–801
   PubMed Web of Science ®Google Scholar
• Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801–805
   PubMed Web of Science ®Google Scholar
• Reiley W. W., Zhang M., Jin W., Losiewicz M., Donohue K. B., Norbury C. C., Sun S. C. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 2006; 7: 411–417
   PubMed Web of Science ®Google Scholar
• Jiang Y. H., Beaudet A. L. Human disorders of ubiquitination and proteasomal degradation. Curr. Opin. Pediatr. 2004; 16: 419–426
   PubMed Web of Science ®Google Scholar
• Haglund K., Dikic I. Ubiquitylation and cell signaling. EMBO J. 2005; 24: 3353–3359
   PubMed Web of Science ®Google Scholar
• Hoeller D., Hecker C. M., Dikic I. Ubiquitin and ubiquitin–like proteins in cancer pathogenesis. Nature Rev. 2006; 6: 776–788
   Web of Science ®Google Scholar
• Fang S., Lorick K. L., Jensen J. P., Weissman A. M. RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin. Cancer Biol. 2003; 13: 5–14
   PubMedGoogle Scholar
• Goy A., Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin. Lymphoma 2004; 4: 230–237
   PubMedGoogle Scholar
• Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004; 22: 304–311
   PubMed Web of Science ®Google Scholar
• Yang Y., Ludwig R. L., Jensen J. P., Pierre S. A., Medaglia M. V., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547–559
   PubMed Web of Science ®Google Scholar
• Weissman A. M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2001; 2: 169–178
   PubMed Web of Science ®Google Scholar
• Vassilev L. T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004; 3: 419–421
   PubMed Web of Science ®Google Scholar
• Vassilev L. T., Vu B. T., Graves B., Carvajal D., Podlaski F., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848
   PubMed Web of Science ®Google Scholar
• Marine J. C., Francoz S., Maetens M., Wahl G., Toledo F., Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006; 13: 927–934
   PubMed Web of Science ®Google Scholar
• Shim J. H., Xiao C., Paschal A. E., Bailey S. T., Rao P., et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 1 2005; 9: 2668–2681
   Google Scholar